March 9 & 10

euroPLX 72 Berlin

Midas Pharma is developing business opportunities worldwide. At euroPLX 72, we want to focus on out-licensing of our FDF-Portfolio.

We offer specialty and niche generic products, including but not limited to new combination products as well as traditional generic developments.

Besides our own Product Pipeline, Midas is in the position to provide you access to third party Registration Dossiers, Development Services and Technologies (e.g. Hot Melt Extrusion under Containment).

Meet us and discuss with our experts about licensing opportunities!


Votre contact

Jonas Ulrich

Jonas Ulrich

Partager cette page